Alternative to LRRK2-IN-1 for Pharmacological Studies of Parkinson's Disease
Kyoko Koshibu1, Judith van Asperen, Helga Gerets
1Neuroscience Therapeutic Area, UCB Biopharma SPRL, Braine-l'Alleud, Belgium.
Background/Aims:
LRRK2 (leucine-rich repeat protein kinase 2) is one of the most commonly accepted genes associated with Parkinson's disease (PD). The overexpression of disease-associated mutations in LRRK2 is toxic to the cells, while reduction or elimination of LRRK2 expression promotes cell health and growth. Thus, the identification of an LRRK2 inhibitor with good physiochemical and pharmacokinetic properties is of great interest for the treatment of PD.
Methods:
In this study, we have investigated LRRK2 compounds, LRRK2-IN-1 and Compound 1, in vitro and in vivo to determine how suitable they are as a selective LRRK2 tool compound.
Results:
We report that Compound 1, patented by GSK, is a potent and selective LRRK2 inhibitor with good blood-brain barrier permeability as reflected by its high brain to plasma ratio in rats. In addition, Compound 1 can significantly promote neurite outgrowth in a primary cortical culture, indicating an optimistic cellular function of this compound in a biological system. In contrast, LRRK2-IN-1 is a less selective LRRK2 inhibitor and has low brain penetration. Furthermore, LRRK2-IN-1 is cyto- and genotoxic, while Compound 1 does not exhibit any toxicity.
Conclusions:
These results suggest that Compound 1 may be a superior tool compound than LRRK2-IN-1 to advance future pharmacological research on LRRK2.
Insights
Compound 1 is a potent and selective LRRK2 inhibitor with excellent brain penetration and no toxicity, making it a promising tool for Parkinson's disease research. It outperformed LRRK2-IN-1 in cellular studies and safety profiles.
Area of Science:
- Neuroscience
- Pharmacology
- Genetics
Background:
- Leucine-rich repeat protein kinase 2 (LRRK2) is a key gene linked to Parkinson's disease (PD).
- Mutant LRRK2 overexpression is toxic; LRRK2 reduction promotes neuronal health.
- Developing selective LRRK2 inhibitors is crucial for PD therapeutics.
Purpose of the Study:
- To evaluate LRRK2 compounds LRRK2-IN-1 and Compound 1 as selective LRRK2 inhibitors.
- To assess their in vitro and in vivo suitability as research tools for Parkinson's disease.
Main Methods:
- In vitro and in vivo studies of LRRK2-IN-1 and Compound 1.
- Assessment of selectivity, brain penetration (brain-to-plasma ratio in rats), and cellular effects (neurite outgrowth).
- Evaluation of cytotoxicity and genotoxicity.
Main Results:
- Compound 1 demonstrated potent and selective LRRK2 inhibition with high blood-brain barrier permeability.
- Compound 1 promoted neurite outgrowth in primary cortical cultures.
- LRRK2-IN-1 showed lower selectivity, poor brain penetration, and was cyto/genotoxic; Compound 1 exhibited no toxicity.
Conclusions:
- Compound 1 is a superior LRRK2 tool compound compared to LRRK2-IN-1.
- Compound 1's properties support its advancement in Parkinson's disease pharmacological research.
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:15Parkinson's Disease: Overview
01:21EPS and iPS Cells in Disease Research
01:37Neural Regulation